Cell Therapy Trial Targets Corneal Disease - Summary - MDSpire
Clinical Guidelines

Cell Therapy Trial Targets Corneal Disease

Aurion Biotech launches phase 3 trial for corneal endothelial cell therapy

  • May 4, 2026

  • 2 min

Share

Aurion Biotech has initiated patient dosing in the pivotal phase 3 ASTRA trial for AURN001, a novel regenerative cell therapy targeting corneal endothelial disease, especially Fuchs dystrophy. The study, conducted at 12 U.S. sites, aims to demonstrate efficacy and safety compared to placebo, focusing on significant visual acuity improvement. AURN001 leverages cultured human corneal endothelial cells combined with a rho-kinase inhibitor, potentially offering a scalable alternative to traditional donor grafts, thus addressing limitations in corneal transplantation and enhancing patient access to treatment.

Original Source(s)

Cell Therapy Trial Targets Corneal Disease

  • May 4, 2026

Related Content

Surgical Confidence with Hydrus®

Nishani Amerasinghe shares surgical tips and pearls for the Hydrus® Microstent

  • May 5, 2026

  • 5 min
The Art of Ophthalmology 2026

Showcasing artwork and images from across the spectrum of ophthalmology

NEI Director Highlights Opportunities for Vision Research

At a time when federal research funding is under close scrutiny, leaders at the National Eye Institute (NEI) are emphasizing continuity, opportunity, and the outsized role of vision science within the broader research ecosystem. Speaking to a packed audience at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Denver, NEI Director Michael F. Chiang, MD, framed recent policy and budget shifts as an evolution in how research is supported.